To the Editor Dr Annane and colleagues1 reported that 28-day mortality (primary end point) did not significantly differ between patients with hypovolemic shock assigned to various colloid fluid therapies (69% of whom received hydroxyethyl starch) vs crystalloid fluid therapies. They also reported that 90-day mortality (one of many secondary end points) was significantly higher with crystalloids.
Brun-Buisson C, Sun J, Natanson C. Mortality in Patients With Hypovolemic Shock Treated With Colloids or Crystalloids. JAMA. 2014;311(10):1068-1069. doi:10.1001/jama.2014.836